AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Enhertu (trastuzumab deruxtecan by Year
Enhertu (trastuzumab deruxtecan — direct product sales) — Europe YoY actual (%) (%)
AstraZeneca Enhertu (trastuzumab deruxtecan: 64.0% in FY2025.
Latest, FY2025
64.0%
Period ended Dec 31, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Form 6-K FY2025Q4 Earnings Release
Where the FY2025 figure comes from
“|| Enhertu | 977 | 79 | 81 | - | - | 668 | 91 | 95 | 207 | 64 | 58 | 102 | 47 | 51”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Enhertu (trastuzumab deruxtecan — direct product sales) — Europe YoY actual (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 64.0% | – | Form 6-K FY2025Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Enhertu (trastuzumab deruxtecan (%), annual FY2025–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-enhertu-eu-act-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.